Stories highlighting important therapy and disease areas.
- New hope for hepatitis B
A number of new therapies for this insidious infection are beginning to arrive, just as the potentially huge Chinese market opens up to Western manufacturers.
Mar 13, 2008
- Oral antidiabetics: now needed more than ever
As the glitazones face safety concerns, the DPP-IV inhibitors are arriving.
Jan 23, 2008
- Diabetes: growing treatment options
A review of the newer therapies for Type II diabetes, now in the spotlight following the safety concerns for Avandia.
Dec 12, 2007
- Pfending off the competition
As generic statins continue to take market share, Pfizer is seeking to defend and grow its revenues from top-seller Lipitor.
Nov 1, 2007
- Cervical cancer - no longer a 'natural born killer'?
With the first HPV vaccine, Gardasil, now having been on the market for more than a year, IMS looks at the competitive landscape for cervical cancer vaccines.
Oct 7, 2007
- Anti -TNF inhibitors in fight for European markets
At the EULAR meeting held in Barcelona in June 2007, the fierce competition in the market for biological rheumatoid arthritis therapies was plain to see.
Jul 31, 2007
- Systemic Hormonal Contraceptives: Schering goes from strength to strength
Patches, intrauterine devices and implants are all making their mark on the birth control market, but Schering AG's oral contraceptives still dominate.
Sep 8, 2006
- Rheumatoid arthritis market moves smoothly ahead
Despite the availability of three successful products, both Roche and BMS have identified the need for further, novel treatments for the crippling autoimmune disorder.
Aug 1, 2006
- Obesity: new products on the horizon
Acomplia is nearing the market, and a number of compounds are in Phase II trials for obesity - a holy grail for the drug industry.
Jun 20, 2006
- Depression – a bleak future?
Many new approaches to the treatment of depression are in the pipeline, but will they be able to overcome the problems of current therapies…?
Mar 2, 2006
